Abstract | BACKGROUND: PATIENTS & METHODS: One hundred South African cisplatin-receiving cancer patients with baseline and follow-up audiometric data were screened for variation in exonic target regions of Otos using direct cycle sequencing. RESULTS: A total of 29 genetic variants were identified. The G alleles of Otos rs77124181 (c.-192-182C>G) and rs2291767 (c.-192-22A>G) were over-represented in ototoxicity-free patients (p = 0.022). Cumulative cisplatin dose and anatomical site of cancer were also associated with ototoxicity, while self-reported ethnicity associated with the ototoxic severity. CONCLUSION: This study indicates a potentially protective role for the variant G alleles of SNPs rs77124181 and rs2291767 in Otos against the development of cisplatin-induced ototoxicity.
|
Authors | Timothy F Spracklen, Heather Whitehorn, Anna Alvera Vorster, Lebogang Ramma, Sameera Dalvie, Rajkumar S Ramesar |
Journal | Pharmacogenomics
(Pharmacogenomics)
Vol. 15
Issue 13
Pg. 1667-76
(Sep 2014)
ISSN: 1744-8042 [Electronic] England |
PMID | 25410892
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- OTOS protein, human
- Proteins
- Cisplatin
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Agents
(toxicity)
- Cisplatin
(toxicity)
- Female
- Genetic Variation
- Hearing Loss, Sensorineural
(chemically induced)
- Humans
- Male
- Middle Aged
- Polymorphism, Single Nucleotide
- Proteins
(genetics)
|